Oculis to Participate at Upcoming April Investor Conferences

Rhea-AI Summary

Oculis Holding AG (Nasdaq: OCS) announces its participation in upcoming investor conferences to present its corporate overview and engage with potential investors. The management will attend the Needham Annual Virtual Healthcare Conference on April 11, 2024, and the Van Lanschot Kempen Life Sciences Conference on April 16-17, 2024, in Amsterdam. Investors can schedule one-on-one meetings to learn more about Oculis's vision and strategic direction in the biopharmaceutical industry.

ZUG, Switzerland and BOSTON, April 04, 2024 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye care, today announced that Oculis’s management will be attending and presenting at the following upcoming investor conferences:

Needham Annual Virtual Healthcare Conference
Format: Corporate presentation
Presenter: Riad Sherif, MD, Chief Executive Officer
Presentation date and time: April 11, 2024 at 8:00 am EDT
Location: Virtual
Webcast: here

Van Lanschot Kempen Life Sciences Conference
Date: April 16-17, 2024
Location: Amsterdam, the Netherlands

The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative to request meetings.

About Oculis

Oculis (Nasdaq: OCS) is a global biopharmaceutical company purposefully driven to save sight and improve eye care. Oculis’s highly differentiated clinical-stage pipeline comprises multiple innovative product candidates in development for eye diseases of high unmet need. It includes OCS-01 eye drops, a topical candidate in Phase 3 development for diabetic macular edema (DME) and inflammation and pain following ocular surgery; OCS-02 eye drops, a topical biologic candidate in Phase 2 development for dry eye disease (DED) and uveitis; and OCS-05, a disease modifying candidate for acute optic neuritis (AON) and other neuro-ophthalmic disorders, such as glaucoma, diabetic retinopathy, geographic atrophy, and neurotrophic keratitis. The first in-patient, proof-of-concept trial with OCS-05 is currently ongoing in France. Headquartered in Switzerland and with operations in the US, Oculis’s goal is to deliver life-changing eye treatments to patients worldwide. The company is led by an experienced management team with a successful track record in the pharmaceutical industry, supported by leading international healthcare investors.

For more information, please visit: www.oculis.com

Oculis Contacts
Ms. Sylvia Cheung, CFO
sylvia.cheung@oculis.com

Investor & Media Relations
LifeSci Advisors
Corey Davis, Ph.D.
cdavis@lifesciadvisors.com
1-212-915-2577

FAQ

When is Oculis participating in the Needham Annual Virtual Healthcare Conference?

Oculis will be presenting at the Needham Annual Virtual Healthcare Conference on April 11, 2024, at 8:00 am EDT.

Where will the Van Lanschot Kempen Life Sciences Conference take place?

The Van Lanschot Kempen Life Sciences Conference will be held in Amsterdam, the Netherlands on April 16-17, 2024.

How can investors schedule meetings with Oculis during the conferences?

Interested investors can contact their respective representative to request one-on-one meetings with Oculis's management team.

What is the ticker symbol for Oculis Holding AG?

The ticker symbol for Oculis Holding AG is OCS.